BioCentury on BioBusiness,
Figure: NPS chronicles
Back to the parent article
Monday, October 22, 2012
Shares of NPS Pharmaceuticals Inc.
(NASDAQ:NPSP) have more than tripled in value since hitting a low of $2.74 in
June 2009. Much of the upward push came from positive news flow for the company's
short bowel syndrome candidate Gattex teduglutide. The analog of glucagon-like
peptide-2 (GLP-2) received a favorable FDA panel vote last week. Europe
approved the drug as Revestive in September. NPS focused on Gattex soon after
receiving a 2006 FDA approvable letter for osteoporosis candidate Preos
recombinant human parathyroid hormone 1-84. The agency requested an additional
Phase III trial, in part to allay concerns about the risk of hypercalcemia
associated with Preos. Last year, NPS said the product, now
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]